{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:15:55Z","timestamp":1772738155837,"version":"3.50.1"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    This study aimed to purify and prepare two isomers of Gadoxetate (Gd-A and Gd-B) from Pumexian and evaluate their stability, magnetic resonance (MR) imaging characteristics, and pharmacokinetics in rabbits. Reversed-phase liquid chromatography was employed to separate Gd-A and Gd-B, achieving purities exceeding 99% for both isomers. These purified isomers were then processed into vacuum-encapsulated solid powders via nitrogen blowing and freeze-drying. Stability assessments were conducted by storing the powders at various temperatures (25\u00b0C, \u221220\u00b0C, 50\u00b0C, and 80\u00b0C) for two months. The results indicated high stability at room temperature (25\u00b0C) and low temperature (\u221220\u00b0C), with both Gd-A and Gd-B maintaining 99% purity. At higher temperatures, purity slightly decreased: Gd-A was 98% at 50\u00b0C and 95% at 80\u00b0C, while Gd-B was 97% at 50\u00b0C and 94% at 80\u00b0C. For the in vivo evaluation, twelve rabbits were randomly assigned to two groups and received intravenous bolus injections of either pure Gd-A or Gd-B, followed by enhanced MR scanning and serial blood sampling. Pharmacokinetic and imaging analyses revealed statistically significant differences (p\u2009&lt;\u20090.05) between the two isomers. Specifically, Gd-A exhibited a shorter time to peak enhancement in liver parenchyma (t\n                    <jats:sub>peak<\/jats:sub>\n                    A\u2009&lt;\u2009t\n                    <jats:sub>peak<\/jats:sub>\n                    B), higher peak signal intensity in the liver parenchyma (SI\n                    <jats:sub>peak<\/jats:sub>\n                    A\u2009&gt;\u2009SI\n                    <jats:sub>peak<\/jats:sub>\n                    B), greater plasma clearance (PCL-A\u2009&gt;\u2009PCL-B), and a shorter half-life (t\n                    <jats:sub>1\/2<\/jats:sub>\n                    A\u2009&lt;\u2009t\n                    <jats:sub>1\/2<\/jats:sub>\n                    B) compared to Gd-B. In conclusion, the vacuum-encapsulated solid powders of Gd-A and Gd-B demonstrate good long-term stability at room or low temperatures while maintaining high purity. Furthermore, the distinct pharmacokinetic profile and imaging characteristics of pure Gd-A suggest its potential value for clinical applications.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0343927","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:31:57Z","timestamp":1772735517000},"page":"e0343927","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Purification and pharmacokinetic study of gadoxetate isomers for enhanced rabbit liver MR imaging"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-8871","authenticated-orcid":true,"given":"Yiling","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JiGen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1964-5098","authenticated-orcid":true,"given":"Xiaodong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"1","key":"pone.0343927.ref001","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/molecules27010058","article-title":"How the chemical properties of GBCAs influence their safety profiles in vivo","volume":"27","author":"QN Do","year":"2021","journal-title":"Molecules"},{"issue":"43","key":"pone.0343927.ref002","doi-asserted-by":"crossref","first-page":"11955","DOI":"10.1039\/D3SC01630G","article-title":"Strategies for chiral separation: From racemate to enantiomer","volume":"14","author":"J Sui","year":"2023","journal-title":"Chem Sci"},{"key":"pone.0343927.ref003","article-title":"Gadolinium Magnetic Resonance Imaging","volume-title":"StatPearls","author":"MA Ibrahim","year":"2023"},{"key":"pone.0343927.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinimag.2023.06.018","article-title":"Four indices on Gd-EOB-DTPA-enhanced MRI can estimate liver functional reserve compared to ICG-R15: A systematic review and meta-analysis","volume":"102","author":"X Ai","year":"2023","journal-title":"Clin Imaging"},{"issue":"2","key":"pone.0343927.ref005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/RLI.0000000000001043","article-title":"Pharmacokinetics, safety, and tolerability of the novel tetrameric, high-relaxivity, macrocyclic gadolinium-based contrast agent gadoquatrane in healthy adults","volume":"59","author":"BM Hofmann","year":"2024","journal-title":"Investigative Radiology"},{"issue":"10","key":"pone.0343927.ref006","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1007\/s00330-018-5403-5","article-title":"The inhibitory effect of gadoxetate disodium on hepatic transporters: A study using indocyanine green","volume":"28","author":"H Akai","year":"2018","journal-title":"Eur Radiol"},{"issue":"3","key":"pone.0343927.ref007","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1148\/radiology.195.3.7754011","article-title":"Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics, and MR imaging","volume":"195","author":"B Hamm","year":"1995","journal-title":"Radiology"},{"issue":"1","key":"pone.0343927.ref008","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3348\/kjr.2023.0507","article-title":"Evaluation and prediction of post-hepatectomy liver failure using imaging techniques: value of gadoxetic acid-enhanced magnetic resonance imaging","volume":"25","author":"K Sofue","year":"2024","journal-title":"Korean J Radiol"},{"issue":"8","key":"pone.0343927.ref009","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1021\/acs.molpharmaceut.1c00206","article-title":"Physiologically based pharmacokinetic modeling of transporter-mediated hepatic disposition of imaging biomarker gadoxetate in rats","volume":"18","author":"D Scotcher","year":"2021","journal-title":"Molecular Pharmaceutics"},{"issue":"2","key":"pone.0343927.ref010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11307-024-01904-2","article-title":"MRI-based cell tracking of OATP-Expressing Cell Transplants by Pre-Labeling with Gd-EOB-DTPA","volume":"26","author":"T Bhattacharyya","year":"2024","journal-title":"Mol Imaging Biol"},{"key":"pone.0343927.ref011","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clinimag.2023.05.018","article-title":"Comparison of noncontrast, dynamic, and hepatobiliary phase abbreviated MRI protocols for detection of hepatic malignancies","volume":"101","author":"JH Lee","year":"2023","journal-title":"Clin Imaging"},{"issue":"4","key":"pone.0343927.ref012","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/08465371221085516","article-title":"Distinction between hepatocellular carcinoma and hypervascular liver metastases in non-cirrhotic patients using gadoxetate disodium-enhanced magnetic resonance imaging","volume":"73","author":"S Ichikawa","year":"2022","journal-title":"Can Assoc Radiol J"},{"issue":"7","key":"pone.0343927.ref013","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1007\/s00330-023-09419-0","article-title":"Deep learning nomogram based on Gd-EOB-DTPA MRI for predicting early recurrence in hepatocellular carcinoma after hepatectomy","volume":"33","author":"M Yan","year":"2023","journal-title":"Eur Radiol"},{"issue":"3","key":"pone.0343927.ref014","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00330-020-07228-3","article-title":"Hepatobiliary phase enhancement of liver metastases on gadoxetic acid MRI: Assessment of frequency and patterns","volume":"31","author":"R Bhayana","year":"2021","journal-title":"Eur Radiol"},{"issue":"3","key":"pone.0343927.ref015","first-page":"874","article-title":"Differentiation of focal nodular hyperplasia and hepatocellular adenoma using qualitative and quantitative imaging features and classification and regression tree analysis","volume":"48","author":"TM Alamri","year":"2023","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"pone.0343927.ref016","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2214\/AJR.22.27989","article-title":"Hepatic adenoma subtypes on hepatobiliary phase of gadoxetic acid-enhanced MRI: Systematic review and meta-analysis","volume":"220","author":"T-H Kim","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"pone.0343927.ref017","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1007\/s00330-024-10829-x","article-title":"Lesions hyper- to isointense to surrounding liver in the hepatobiliary phase of gadoxetic acid-enhanced MRI","volume":"34","author":"A Furumaya","year":"2024","journal-title":"Eur Radiol"},{"issue":"6","key":"pone.0343927.ref018","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1021\/ic981072i","article-title":"Synthesis and physicochemical characterization of a new gadolinium chelate: The liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPA","volume":"38","author":"H Schmitt-Willich","year":"1999","journal-title":"Inorg Chem"},{"issue":"2","key":"pone.0343927.ref019","doi-asserted-by":"crossref","first-page":"110","DOI":"10.24920\/003794","article-title":"Assessing liver function by T1 Maps on Gd-EOB-DTPA-Enhanced MRI for up to 50 Min in Rat Models of Liver Fibrosis: A Longer hepatobiliary time period may help","volume":"36","author":"J Xu","year":"2021","journal-title":"Chin Med Sci J"},{"issue":"3","key":"pone.0343927.ref020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/RLI.0000000000000622","article-title":"Dual plasma sampling method to determine the hepatic and renal clearance of the 2 diastereoisomers of Gd-EOB-DTPA","volume":"55","author":"X Yuan","year":"2020","journal-title":"Invest Radiol"},{"issue":"1","key":"pone.0343927.ref021","doi-asserted-by":"crossref","first-page":"21731","DOI":"10.1038\/s41598-021-00974-4","article-title":"An NMR relaxometry approach for quantitative investigation of the transchelation of gadolinium ions from GBCAs to a competing macromolecular chelator","volume":"11","author":"P Werner","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0343927.ref022","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s007750000195","article-title":"Stereospecific binding of MRI contrast agents to human serum albumin: The case of Gd-(S)-EOB-DTPA (Eovist) and its (R) isomer","volume":"6","author":"L Vander Elst","year":"2001","journal-title":"J Biol Inorg Chem"},{"issue":"6","key":"pone.0343927.ref023","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/bdd.1907","article-title":"Quantitative evaluation of biliary elimination of gadoxetate, a magnetic resonance imaging contrast agent, via geometrical isomer-specific transporting system in rats","volume":"35","author":"J Ogawa","year":"2014","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"pone.0343927.ref024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/toxics10020056","article-title":"Altered plasma mitochondrial metabolites in persistently symptomatic individuals after a GBCA-Assisted MRI","volume":"10","author":"D Denmark","year":"2022","journal-title":"Toxics"},{"issue":"3","key":"pone.0343927.ref025","article-title":"Safety of gadoxetate disodium for hepatobiliary MRI in children and adolescents","volume":"311","author":"PH Kim","year":"2024","journal-title":"Radiology"},{"issue":"4","key":"pone.0343927.ref026","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.ajkd.2020.07.012","article-title":"Risks and options with gadolinium-based contrast agents in patients with CKD: A review","volume":"77","author":"MR Rudnick","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"pone.0343927.ref027","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.crad.2021.12.020","article-title":"Gadolinium deposition in the brain is related to various contrast agents: A matched case-control study","volume":"77","author":"Q Bi","year":"2022","journal-title":"Clin Radiol"},{"issue":"13","key":"pone.0343927.ref028","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1007\/s00247-021-05134-4","article-title":"Evaluation of the effect of multiple administrations of gadopentetate dimeglumine or gadoterate meglumine on brain T1-weighted hyperintensity in pediatric patients","volume":"51","author":"AJ Towbin","year":"2021","journal-title":"Pediatr Radiol"},{"issue":"1","key":"pone.0343927.ref029","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jmri.29389","article-title":"Gadolinium contrast agent deposition in children","volume":"61","author":"M Ouyang","year":"2025","journal-title":"J Magn Reson Imaging"},{"issue":"7","key":"pone.0343927.ref030","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1007\/s00330-022-09297-y","article-title":"Brain deposition of gadobutrol in children-a cross-sectional and longitudinal MRI T1 mapping study","volume":"33","author":"D Gr\u00e4fe","year":"2023","journal-title":"Eur Radiol"},{"issue":"8","key":"pone.0343927.ref031","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1177\/02841851231171660","article-title":"The need for prophylactic hemodialysis to protect against nephrogenic systemic fibrosis in patients with end-stage renal disease receiving gadolinium-based contrast agents","volume":"64","author":"Y Lee","year":"2023","journal-title":"Acta Radiol"},{"issue":"8","key":"pone.0343927.ref032","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/diagnostics12081816","article-title":"Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager","volume":"12","author":"S Gallo-Bernal","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"pone.0343927.ref033","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/jimaging8100254","article-title":"Gadolinium and bio-metal association: A concentration dependency tested in a renal allograft and investigated by micro-synchrotron XRF","volume":"8","author":"W Osterode","year":"2022","journal-title":"J Imaging"},{"issue":"2","key":"pone.0343927.ref034","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00204-021-03189-8","article-title":"Gadolinium: Pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration","volume":"96","author":"J Davies","year":"2022","journal-title":"Arch Toxicol"},{"issue":"4","key":"pone.0343927.ref035","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/jcph.1762","article-title":"Unusual distribution kinetics of gadoxetate in healthy human subjects genotyped for OATP1B1: Application of population analysis and a minimal physiological-based pharmacokinetic model","volume":"61","author":"M Weiss","year":"2021","journal-title":"J Clin Pharmacol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0343927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:32:03Z","timestamp":1772735523000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0343927"}},"subtitle":[],"editor":[{"given":"Roy P.","family":"Planalp","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0343927","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}